Viromed Medical AG has successfully completed the capital increase it announced earlier, placing 450,000 new registered no-par value shares at a placement price of EUR 4.50 per share. The gross proceeds of approximately EUR 2 million will be used to finance the company's working capital. The capital increase was carried out by partially utilizing the Authorized Capital 2025 and with the exclusion of shareholders' subscription rights. Subject to registration in the commercial register, the share capital will increase from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000.
The completion of this capital increase is significant because it strengthens Viromed's financial position and provides the liquidity needed to support its ongoing operations. The company specializes in the development, manufacture, and distribution of medical products, with a focus on innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. Since its stock exchange listing in October 2022, Viromed has built a broad customer base in the DACH region and beyond. The fresh capital will help the company pursue its goal of further advancing the use of cold plasma technology in medicine and realizing corresponding growth potential.
The exclusion of shareholders' subscription rights means existing shareholders did not have the opportunity to participate in the placement, which could lead to dilution of their holdings. However, the successful placement at EUR 4.50 per share indicates investor confidence in Viromed's business model and growth strategy. The capital increase, as reported by NEWMEDIAWIRE, underscores the company's ability to raise funds in a challenging market environment.
Viromed's focus on cold plasma technology positions it in a niche segment of the medical technology market. Cold plasma has shown promise in various medical applications, including wound healing and infection control, and the company aims to expand its use. The additional working capital will enable Viromed to invest in sales and marketing, research and development, and potentially accelerate product adoption. More details about the company can be found at www.viromed-medical-ag.de.
The capital increase is a key step for Viromed as it seeks to capitalize on the growing interest in cold plasma technology. With the proceeds, the company can strengthen its operational footing and continue to develop its product portfolio. The transaction also demonstrates the support of investors who subscribed to the new shares, which bodes well for Viromed's future growth prospects.
